PORTLAND, Maine--(BUSINESS WIRE)--Covetrus (NASDAQ: CVET), a global leader in animal-health technology and services, has named Arman Samani to the role of chief product officer (CPO). Arman will be responsible for developing and driving the vision, roadmap and innovation strategy across Covetrus software products to fuel the company’s future growth. Arman will lead global product teams, reporting into Georgia Wraight, executive vice president and president, Global Technology Solutions (GTS).
“A core area of investment, priority and focus for Covetrus is our product management organization,” said Wraight. “The CPO plays an integral role in unifying our product portfolio to deliver integrated technology solutions for our customers. We are excited to welcome Arman to the Covetrus team and look forward to his expertise and experience driving the realization of our long-term innovation strategy.”
In his new role, Arman becomes the senior most product manager at Covetrus and will partner with Todd Haedrich, chief commercial officer of GTS, and Tim Brewer, chief technology officer of GTS, in ensuring that the “voice of the customer” is reflected throughout Covetrus’ suite of products, which includes solutions for practice management, client communications and prescription management.
Arman brings more than 20 years of experience in healthcare industry software solutions at companies including 3M, Allscripts, MEDHOST and AdvancedMD. Arman was most recently the chief operating officer of AdvancedMD, where he was responsible for product management, product marketing, engineering, platform operations, and customer and technical services. Having led more than just product management, Arman understands the complexities of integrating teams and creating a cohesive unit in order to drive products to market. He is very focused on innovation and has also been the driver of migrating legacy technology to the public Cloud, as well as building cloud-native healthcare solutions.
Arman holds a B.S. in Economics from the University of Texas at Austin, and a M.B.A. from the University of North Carolina at Chapel Hill.
About Covetrus
Covetrus is a global animal-health technology and services company dedicated to empowering veterinary practice partners to drive improved health and financial outcomes. We are bringing together products, services and technology into a single platform that connects our customers to the solutions and insights they need to work best. Our passion for the well-being of animals and those who care for them drives us to advance the world of veterinary medicine. Covetrus is headquartered in Portland, Maine, with more than 5,500 employees, serving over 100,000 customers around the globe. Learn more at covetrus.com.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including statements about our plans, objectives, expectations, and intentions. Such statements are subject to numerous risks and uncertainties and actual results could differ materially from those anticipated due to a number of factors including, but not limited to, risks associated with our management transition; the ability to successfully integrate operations and employees; and those additional risks discussed under the heading "Risk Factors" in our Annual Report on Form 10-K filed on March 3, 2020, our Quarterly Report on Form 10-Q to be filed with the SEC on May 14, 2020, and in our other SEC filings. Our forward-looking statements are based on current beliefs and expectations of our management team and, except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise. Investors are cautioned not to place undue reliance on these forward-looking statements.
